Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

After failing the Primary endpoint in its PEPITES Phase 3 trial, DBV is moving ahead with an FDA filing. Does the drug have a chance at approval?

Ticker(s): DBVT, AIMT

Who's the expert?

Name: Dr Christina Ciaccio - MD

Institution: The University of Chicago

  • Acting Chief of Allergy/Immunology and Pediatric Pulmonary and Sleep Medicine, Associate Professor of Pediatrics and Medicine, and Clinical Director of the Food Allergy Program at the University of Chicago.
  • Treats on average 3 peanut allergy patients each day and is in clinic 3 days/week.
  • Research focus is on determining influences of allergic sensitization and advancing the treatment of food allergy through clinical trials.

Interview Questions
Q1.

Please describe your background treating peanut allergies. 

Added By: joe_mccann
Q2.

What is your initial impression of the PEPITES data? Does a 35% response vs. 13% response for the treatment arm vs. placebo look compelling to you?

Added By: joe_mccann
Q3.

The company is touting the success on the secondary endpoint of cumulative reactive dose of 900mg vs. 360mg for active arm vs. placebo. This increase from baseline was stat sig with a p value of <.001. Does this result look clinically relevant to you?

Added By: joe_mccann
Q4.

Safety and tolerability was in line with Phase 2b results. Do any adverse events or safety issues stand out to you given the level of efficacy seen?

Added By: joe_mccann
Q5.

If you were on an advisory panel for the FDA and there were no major surprises in the additional data presentations, would you recommend approval based on the established profile?

Why or why not?

Added By: joe_mccann
Q6.

On a scale of 1-10 how excited for Viaskin in peanut allergies are you after this data?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.